Business
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
-Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) --
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"-Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentation\nMARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead product candidate, PH-762, an INTASYL compound. PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers. (NCT 06014086). This open-label Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of IT PH-762 in Stages 1,2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC represent 77% of all new cSCC annually. There are no drug products approved for treatment of Stages 1 and 2 cSCC. The data will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, Illinois. Title: INTASYL™ PH-762: PD-1 Intratumoral Immunotherapy for Cutaneous Carcinoma Poster Number: TPS9620Topic: Melanoma/Skin CancerPresenting Author: Mary Spellman, M.D.Date and Time: June 1, 2024: 1:30-4:30 PM CDT About Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. For additional information, visit the Company’s website, www.phiopharma.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\" \"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\" \"forecast,\" \"target,\" \"predict,\" \"could\" and...